Fukewai Application Scope

Anlotinib is an oral multi-target tyrosine kinase inhibitor that suppresses tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, and c-Kit.

fukewai

Characteristics

Ingredients: Anlotinib Hydrochloride

Properties:
- Multi-targeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR, FGFR, PDGFR, and c-Kit
- Effectively suppressing tumor angiogenesis and growth.
Packaging Specification:
- Typically supplied in blister packs containing 8 mg capsules;
- Packaging details may vary by manufacturer.

Storage: Store in a cool, dry place away from direct sunlight and moisture.
Expiry Date: Refer to the packaging for the specific expiration date.
Executive Standard: Manufactured by national pharmaceutical standards; specific codes may vary by region.
Approval Number: Refer to the national drug approval registry for the specific approval number.
Date of Revision: Refer to the latest prescribing information for the revision date.
Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Guidelines for the Use of Fukewai

Dosage and Administration:
- Recommended dosage is 12 mg orally once daily for 14 consecutive days
- Followed by 7 days off treatment, constituting a 21-day cycle.
- Dosage may be adjusted based on patient tolerance and clinical response.
Adverse Reactions:
- Common side effects include hypertension, hand-foot syndrome, fatigue, anorexia, and diarrhea.
- Serious adverse effects may involve hemorrhage, thrombosis, and cardiac dysfunction.
Contraindications:
- Patients with known hypersensitivity to anlotinib or any excipients.
- Not recommended for patients with uncontrolled hypertension or significant cardiovascular disease.
Precautions:
- Monitor blood pressure regularly during treatment.
- Use with caution in patients with a history of bleeding disorders or recent surgery.
- Pregnant or breastfeeding women should consult their healthcare provider before use.

Fukewai Interactions

Drug Interactions:
- Caution is advised when co-administering with other antihypertensive agents due to the risk of additive blood pressure-lowering effects.
- Potential interactions with CYP3A4 inhibitors or inducers may affect anlotinib plasma concentrations; monitor accordingly.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.